A biotechnology company specialized in virology diagnostics
AdvancedDx Biological Laboratories (ABLDx) is a virologic diagnostic solutions company focused on commercializing solutions that will advance public health in the Americas. ABLDx will be initially focused on fighting the COVID-19 global pandemic by bringing tests to local communities in the U.S. With a philosophy that “to measure is to know,” ABLDx recognizes that testing lies at the critical intersection of patient care, the collection of sufficient data to inform vaccine development, and the need to create public health and safety measures.
Improving Disease Management
Advanced Biological Laboratories (ABL), S.A., the parent company of ABLDx, with headquarters in Luxembourg, has a 10-year track record in virology and infectious disease testing. ABL’s products offer to infectious disease clinicians, virology and microbiology laboratories optimal and efficient solutions (assays and software systems related to HIV, Tuberculosis, HCV, HBV, HPV, CMV, HPV, Flu, and 16s RNA) for sequencing (DeepChek®) clinical genotyping, viral load (UltraGene™) and drug resistance analysis, as well as, powerful fully-integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data.
Founder and Chairman
In the early-1990’s Dr. Sayada moved into the Diagnostic industry at Roche Diagnostics in France, where his contributions led to accelerated commercialization of the first infectious disease molecular diagnostics suite of Products, Amplicor from Roche Molecular, in France, and in Europe indicated for monitoring of adults and children with HIV-1, HepC, Chlamydia and Tuberculosis infection, and diagnosis of HIV & HCV RNA in blood banks in France.
Over the years, Dr. Sayada has formed and led several new biotechnology companies, in Molecular diagnostics and in Therapeutics Development, in Europe and in the US, to develop innovative diagnostics, antivirals and antibiotics products, leading to several successful registrations and commercializations.
Since 2006, Dr. Sayada has been leading ABL SA to build a fully integrated Diagnostic company, from R&D, to manufacturing, regulatory, marketing and commercial, with the focus to develop proprietary innovative molecular diagnostics and IT medical software and solutions, in Infectious diseases.
Dr. Sayada serves as an Independent Director for GenosciencPharma SA (France) and Qode Healthcare Solutions (South Africa).
He holds a PhD in Microbiology from the University of Chatenay Malabry in south of Paris, and a MD from Paris Robert Debre Hospital University where he trained as a microbiology molecular biologist.
Vice President, Regulatory Affairs
He earned a 2-year technical degree in Statistics from UBS University. He was trained in computer programming, data processing and applied statistics to medicine (Paris University). He made a 1-year University degree in Data Protection (Paris University) and parallel training to specialize in health personal data protection. With rich experience in the medical arena, Mr. Boulmé has published 12 peer-reviewed articles as a co-author.
Vice President, Diagnostics Solutions
He developed web applications for genotyping through sequencing of viral pathogens (HIV, viral hepatitis B/C, etc.) including proprietary bioinformatics pipelines and clinical interpretation modules.
In 2010, Mr. Gonzalez moved into the business and technical development of a line of proprietary molecular biology products intended to be used for genotyping and personalized medicine in the field of infectious diseases. He supervised the R&D teams and their activities (bioinformaticians, lab researchers, technicians, QC managers, web-developers, etc.), developed the commercialization of the diagnostics line of products on five continents and established a network of sales based on more than 25 local distributors and 150 direct customers in Africa, America, Asia, Europe and Oceania.
In charge of the Diagnostics business unit of the global ABL-SA group, he now brings expertise in molecular diagnostic and bioinformatics, as well as proven success in commercial product launch and lifecycle management to coordinate marketing, sales and business development (both B2B and B2C) of molecular biology software and assays/instruments used for diagnostics.
He holds a master of science bachelor’s degree in biotechnologies from the ESIL/Luminy engineering school (France).
Affiliations & Accreditations
Our team has studied and worked with these universities, research organizations and healthcare affiliates.